Frecuencia del síndrome metabólico y factores de riesgo en adultos con y sin diabetes mellitus e hipertensión arterial

Objetivo Determinar la frecuencia y factores de riesgo para Síndrome Metabólico (SM) en adultos con Diabetes mellitus, hipertensión arterial y sin diabetes-hipertensión.Material y Métodos Se realizó un estudio transversal analítico en derechohabientes de ambos sexos y mayores de 20 años de los servicios de consulta externa del HGZ No. 1 IMSS Colima, México. Las variables estudiadas fueron edad, IMC, diámetro de la cintura, grado de escolaridad, estado socioeconómico, grado de actividad física, tabaquismo, antecedentes familiares para diabetes e hipertensión arterial (HTA) y parámetros bioquímicos como glucosa, colesterol HDL, triglicéridos.Resultados Se estudiaron 417 pacientes (170 hombres y 247 mujeres), con un promedio de edad 53,2 ± 13,4 años (intervalo 20 a 86 años). La frecuencia global del SM fue del 52,3 % (56 % mujeres y 46,4 % hombres). Mientras que la frecuencia del SM fue de 50 % en DM2, 42% en HTA, 80 % DM2 + HTA y 28,2 % sin DM o HTA. La frecuencia del tabaquismo fue del 27,8 % y fue un factor de riesgo importante para la totalidad de pacientes con SM, en DM2 y en DM2+HAT.Conclusiones La frecuencia del SM en adultos fue del 52,3 %, las mujeres fueron más afectadas y el tabaquismo fue el factor de riesgo más importante.Objective Determinate the frequency and the risk factors for Metabolic Syndrome in adults with diabetes mellitus, Hypertension and without Diabetes- Hypertension.materials and Methods We realized a cross-sectional study in patients of both sexes and older than 20 years of the “Hospital General de Zona 1 IMSS” in Colima, Mexico. The variables studied were: age, BMI, waist circumference, cigarette smoking, and family history of diabetes and hypertension, and biochemical parameters, such as glucose, HDL cholesterol and triglycerides.Results A total of 417 persons were enrolled (170 men and 247 women), with an age average of 53.2 ± 13.4 years (age range, 20 to 86 years). The global frequency of the metabolic syndrome was 52.3 % (56 % in women and 46.4 % in men). While the MS frequency was 50 % in DM2, 42 % in hypertension, 80 % in DM2+hypertension and 28.2 % without DM2 and hypertension. The cigarette smoking frequency was 27.8 %, and it was an important risk factor for the totally of patients with MS, in DM2 and in DM2+hypertension.Conclusions The frequency of MS in adults was 52.3 %, women were the most affected, and cigarette smoking was the most important risk factor

Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study

Objective. To evaluate the effect of anti-TNF agents plus synthetic disease modifying antirheumatic drugs (DMARDs) versus DMARDs alone for ankylosing spondylitis (AS) with reduced pulmonary function vital capacity (FVC%). Methods. In an observational study, we included AS who had FVC% <80% at baseline. Twenty patients were taking DMARDs and 16 received anti-TNF + DMARDs. Outcome measures: changes in FVC%, BASDAI, BASFI, 6-minute walk test (6MWT), Borg scale after 6MWT, and St. George’s Respiratory Questionnaire at 24 months. Results. Both DMARDs and anti-TNF + DMARDs groups had similar baseline values in FVC%. Significant improvement was achieved with anti-TNF + DMARDs in FVC%, at 24 months, when compared to DMARDs alone (P=0.04). Similarly, patients in anti-TNF + DMARDs group had greater improvement in BASDAI, BASFI, Borg scale, and 6MWT when compared to DMARDs alone. After 2 years of follow-up, 14/16 (87.5%) in the anti-TNF + DMARDs group achieved the primary outcome: FVC% ≥80%, compared with 11/20 (55%) in the DMARDs group (P=0.04). Conclusions. Patients with anti-TNF + DMARDs had a greater improvement in FVC% and cardiopulmonary scales at 24 months compared with DMARDs. This preliminary study supports the fact that anti-TNF agents may offer additional benefits compared to DMARDs in patients with AS who have reduced FVC%